Staff Profile

Roles and Responsibilities

• Professor of Cancer Genetics at Newcastle University

Qualifications

• 1992 BSc (Honours) first class in Applied Biology from Liverpool Polytechnic
• 1996 DPhil, University of York

Previous Positions

• 1990 - 1991, Molecular Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, U.K.
• 1992 - 1996, DPhil. student, Department of Biology, University of York, York, U.K.
• 1996 - 1998,  Postdoctoral Research Fellow, Department of Cancer Cell Biology, Division of Toxicology, School of Public Health, Harvard University, Boston, Massachusetts, U.S.A. (Leukemia Society of America Fellow).
• 1998 – 2001,  Independent Research Fellow, Molecular Epidemiology Unit, Academic Unit of Epidemiology and Health Services Research, School of Medicine, University of Leeds, Leeds, U.K. (Kay Kendall Leukaemia Research Fellow).
• 2001 – 2004, Senior Research Fellow, Epidemiology and Genetics Unit, School of Medicine, University of Leeds, Leeds, U.K.
• 2004 – 2007, Independent Principal Investigator, Department of Biology, University of York. York, U.K.
• 2007 - 2015, Senior Lecturer in Molecular Carcinogenesis, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, U.K.
• 2015 - present. Professor of Cancer Genetics, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, U.K.

Areas of expertise

• Acute myeloid leukaemia - genetic susceptibility, disease prognostication, disease evolution, tumour heterogeneity, development of novel therapies
• Chronic lymphocytic leukaemia - genetic susceptibility, disease prognostication
• Therapy-induced cancer and other treatment complications - genetic susceptibility and pathogenesis

Google scholar: Click here.
SCOPUS: Click here.

Research Interests

Acute myeloid leukaemia - genetic susceptibility, disease prognostication, disease evolution, tumour heterogeneity, development of novel therapies.

Chronic lymphocytic leukaemia - genetic susceptibility, disease prognostication

Therapy-induced cancer and other treatment complications - genetic susceptibility and pathogenesis.

PhD positions

Self-funded PhD applications are welcome.

Esteem Indicators

Leukemia Society of America Fellow, Harvard University (1997)

Kay Kendall Leukaemia Research Fellow, Leeds University (1999)

American Association for Cancer Research Molecular Epidemiology Award for Excellence (2003)

Funding

Blood Cancer UK (https://bloodcancer.org.uk/)

JGW Patterson Foundation

Medical Research Council (MRC)

Newcastle Healthcare Charity

Bright Red

Children with Cancer

Gilead Sciences

• Articles

  • Stolzel F, Fordham SE, Nandana D, Lin W-Y, Blair H, Elstob C, Bell HL, Mohr B, Ruhnke L, Kunadt D, Dill C, Allsop D, Piddock R, Soura E-N, Park C, Fadly M, Rahman T, Alharbi A, Wobus M, Altmann H, Rollig C, Wagenfuhr L, Jones GL, Menne T, Jackson GH, Marr HJ, Fitzgibbon J, Onel K, Meggendorfer M, Robinson A, Bziuk Z, Bowes E, Heidenreich O, Haferlach T, Villar S, Ariceta B, Diaz RA, Altschuler SJ, Wu LF, Prosper F, Montesinos P, Martinez-Lopez J, Bornhauser M, Allan JM. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia. JCI Insight 2023, 8(2), e150368.
  • Shih AJ, Jun T, Skol AD, Bao R, Huang L, Vora S, McNerney ME, Hungate EA, Le Beau MM, Larson RA, Elliott A, Lu H-M, Huether R, Hernandez F, Stolzel F, Allan JM, Onel K. Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. British Journal of Haematology 2022, epub ahead of print.
  • Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, Wilson A, Nizami S, Nakjang S, Zhou P, Schwab C, Sinclair P, Russell LJ, Coxhead J, Halsey C, Allan JM, Harrison CJ, Moorman AV, Heidenreich O, Vormoor J. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine 2022, 3(8), 100717.
  • Tirtakusuma R, Szoltysek K, Milne P, Grinev VV, Ptasinska A, Chin PS, Meyer C, Nakjang S, Hehir-Kwa JY, Williamson D, Cauchy P, Keane P, Assi SA, Ashtiani M, Kellaway SG, Imperato MR, Vogiatzi F, Schweighart EK, Lin S, Wunderlich M, Stutterheim J, Komkov A, Zerkalenkova E, Evans P, McNeill H, Elder A, Martinez-Soria N, Fordham SE, Shi Y, Russell LJ, Pal D, Smith A, Kingsbury Z, Becq J, Eckert C, Haas OA, Carey P, Bailey S, Skinner R, Miakova N, Collin M, Bigley V, Haniffa M, Marschalek R, Harrison CJ, Cargo CA, Schewe D, Olshanskaya Y, Thirman MJ, Cockerill PN, Mulloy JC, Blair HJ, Vormoor J, Allan JM, Bonifer C, Heidenreich O, Bomken S. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood 2022, 140(17), 1875-1890.
  • Marin-Rubio JL, Peltier-Heap RE, Duenas ME, Heunis T, Dannoura A, Inns J, Scott J, Simpson AJ, Blair HJ, Heidenreich O, Allan JM, Watt JE, Martin MP, Saxty B, Trost M. A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia. Journal of Medicinal Chemistry 2022, 65(18), 12014-12030.
  • Lin W-Y, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann W-K, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Stolzel F, Onel K, Allan JM. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications 2021, 12(1), 6233.
  • Lin W-Y, Fordham SE, Sunter N, Elstob C, Rahman T, Willmore E, Shepherd C, Strathdee G, Mainou-Fowler T, Piddock R, Mearns H, Barrow T, Houlston RS, Marr H, Wallis J, Summerfield G, Marshall S, Pettitt A, Pepper C, Fegan C, Forconi F, Dyer MJS, Jayne S, Sellors A, Schuh A, Robbe P, Oscier D, Bailey J, Rais S, Bentley A, Cawkwell L, Evans P, Hillmen P, Pratt G, Allsup DJ, Allan JM. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature Communications 2021, 12(1), 665.
  • Wang J, Clay-Gilmour AI, Karaesmen E, Rizvi A, Zhu Q, Yan L, Preus L, Liu S, Wang Y, Griffiths E, Stram DO, Pooler L, Sheng X, Haiman C, Van Den Berg D, Webb A, Brock G, Spellman S, Pasquini M, McCarthy P, Allan J, Stolzel F, Onel K, Hahn T, Sucheston-Campbell LE. Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Frontiers in Genetics 2021, 12, 554948.
  • Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst-Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pajak A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dorr M, Lerch MM, Volker U, Volzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S, Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovascular Disorders 2019, 19(1), 240.
  • Speedy HE, Beekman R, Chapaprieta V, Orlando G, Law PJ, Martin-Garcia D, Gutierrez-Abril J, Catovsky D, Bea S, Clot G, Puiggros M, Torrents D, Puente XS, Allan JM, Lopez-Otin C, Campo E, Houlston RS, Martin-Subero JI. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nature Communications 2019, 10(1), 3615.
  • Vijayakrishnan J, Qian M, Studd JB, Yang W, Kinnersley B, Law PJ, Broderick P, Raetz EA, Allan J, Pui C-H, Vora A, Evans WE, Moorman A, Yeoh A, Yang W, Li C, Bartram CR, Mullighan CG, Zimmerman M, Hunger SP, Schrappe M, Relling MV, Stanulla M, Loh ML, Houlston RS, Yang JJ. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications 2019, 10(1), 5348.
  • Allan JM. Genetic susceptibility to breast cancer in lymphoma survivors. Blood 2019, 133(10), 1004-1006.
  • Went M, Sud A, Speedy H, Sunter NJ, Forsti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jockel K-H, Nickel J, Nothen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal 2019, 9(1), 1.
  • Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell 2018, 34(4), 626-642.e8.
  • Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.
  • Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2018, 9(1), 1340.
  • Hyatt S, Jones RE, Heppel NH, Grimstead JW, Fegan C, Jackson GH, Hills R, Allan JM, Pratt G, Pepper C, Baird DM. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology 2017, 178(1), 94-98.
  • Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. European Journal of Cancer 2017, 71, 15-24.
  • Law PJ, Sud A, Mitchell JS, Henrion M, Orlando G, Lenive O, Broderick P, Speedy HE, Johnson DC, Kaiser M, Weinhold N, Cooke R, Sunter NJ, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Carmichael J, Bailey JR, Pratt G, Rahman T, Pepper C, Fegan C, von Strandmann EP, Engert A, Försti A, Chen BW, da Silva MI, Thomsen H, Hoffmann P, Noethen MM, Eisele L, Jöckel KH, Allan JM, Swerdlow AJ, Goldschmidt H, Catovsky D, Morgan GJ, Hemminki K, Houlston RS. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific Reports 2017, 7, 41071.
  • Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang YW, Zheng TZ, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang ZM, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RCH, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJS, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager SL. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications 2017, 8, 14175.
  • McCormick A, Earp E, Elliot K, Cuthbert G, O'Donnell R, Wilson BT, Sutton R, Leeson C, Thomas HD, Blair H, Fordham S, Lunec J, Allan J, Edmondson RJ. Functional characterisation of a novel ovarian cancer cell line, NUOC-1. Oncotarget 2017, 8(16), 26832-26844.
  • Vijayakrishnan J, Kumar R, Henrion MYR, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jockel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia 2017, 31(3), 573-579.
  • Sasaki MM, Skol AD, Hungate EA, Bao RY, Huang L, Kahn SA, Allan JM, Brant SR, McGovern DPB, Peter I, Silverberg MS, Cho JH, Kirschner BS, Onel K. Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2016, 22(1), 20-27.
  • Kandaswamy R, Sava GP, Speedy HE, Beà S, Martin-Subero JI, Studd JB, Migliorini G, Law PJ, Puente XS, Martín-García D, Salaverria I, Gutiérrez-Abrill J, López-Otín C, Catovsky D, Allan JM, Campo E, Houlston RS. Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. Cell Reports 2016, 16(8), 2061-2067.
  • Vijayakrishnan J, Henrion M, Moorman AV, Fiege B, Kumar R, da Silva MI, Holroyd A, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Bartram CR, Schrappe M, Greaves M, Hemminki K, Harrison CJ, Stanulla M, Houlston RS. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Scientific Reports 2015, 5, 15065.
  • Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FEB, Allan JM, Pollard JR, Curtin NJ. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 2015, 6(32), 32396-32409.
  • Freitag DF, Butterworth AS, Willeit P, Howson JMM, Burgess S, Kaptoge S, Young R, Ho WK, Wood AM, Sweeting M, Spackman S, Staley JR, Ramond A, Harshfield E, Nielsen SF, Grande P, Lange LA, Bown MJ, Jones GT, Scott RA, Bevan S, Porcu E, Thorleifsson G, Zeng LY, Kessler T, Nikpay M, Do R, Zhang WH, Hopewell JC, Kleber M, Delgado GE, Nelson CP, Goel A, Bis JC, Dehghan A, Ligthart S, Smith AV, Qu LM, van 't Hof FNG, de Bakker PIW, Baas AF, van Rij A, Tromp G, Kuivaniemi H, Ritchie MD, Verma SS, Crawford DC, Malinowski J, de Andrade M, Kullo IJ, Peissig PL, McCarty CA, Bottinger EP, Gottesman O, Crosslin DR, Carrell DS, Rasmussen-Torvik LJ, Pacheco JA, Huang J, Timpson NJ, Kettunen J, Ala-Korpela M, Mitchell GF, Parsa A, Wilkinson IB, Gorski M, Li Y, Franceschini N, Keller MF, Ganesh SK, Langefeld CD, Bruijn L, Brown MA, Evans DM, Baltic S, Ferreira MA, Baurecht H, Weidinger S, Franke A, Lubitz SA, Muller-Nurasyid M, Felix JF, Smith NL, Sudman M, Thompson SD, Zeggini E, Panoutsopoulou K, Nalls MA, Singleton A, Polychronakos C, Bradfield JP, Hakonarson H, Easton DF, Thompson D, Tomlinson IP, Dunlop M, Hemminki K, Morgan G, Eisen T, Goldschmidt H, Allan JM, Henrion M, Whiffin N, Wang YF, Chubb D, Houlston RS, Iles MM, Bishop DT, Law MH, Hayward NK, Luo Y, Nejentsev S, Barbalic M, Crossman D, Sanna S, Soranzo N, Markus HS, Wareham NJ, Rader DJ, Reilly M, Assimes T, Harris TB, Hofman A, Franco OH, Gudnason V, Tracy R, Psaty BM, Farrall M, Watkins H, Hall AS, Samani NJ, Marz W, Clarke R, Collins R, Kooner JS, Chambers JC, Kathiresan S, McPherson R, Erdmann J, Kastrati A, Schunkert H, Stefansson K, Thorsteinsdottir U, Walston JD, Tybjaerg-Hansen A, Alam DS, Majumder AA, Di Angelantonio E, Chowdhury R, Nordestgaard BG, Saleheen D, Thompson SG, Danesh J, Interleukin 1 Genetics Consortium, European Prospective Invest Canc, Aneurysm Consortium, Elect Med Records & Genomics Netwo, UK 10K Consortium, European Prospective Invest Canc, METASTROKE Consortium, Chronic Kidney Dis Genetics Consor, Cohorts Heart & Aging Res Genomic, Australo-Anglo-Amer Spondyloarthri, Australian Asthma Genetics Consort, Atrial Fribrillation Genetics Cons, Cohorts Heart & Aging Res Genomic, Consortium Juvenile Arthritis Gene, Arthritis Res UK Osteoarthritis Ge, Int Parkinson's Dis Consortium, Breast Canc Assoc Consortium, Melanoma Genetics Consortium, Cohorts Heart & Aging Res Genomic, Myocardial Infarction Genetics Con. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes & Endocrinology 2015, 3(4), 243-253.
  • Wade MA, Sunter NJ, Fordham SE, Long A, Masic D, Russell J, Harrison CJ, Rand V, Elstob C, Bown N, Rowe D, Lowe C, Cuthbert G, Bennett S, Crosier S, Bacon CM, Onel K, Scott K, Scott D, Travis LB, May FEB, Allan JM. c-MYC is a radiosensitive locus in human breast cells. Oncogene 2015, 34, 4985-4994.
  • Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, Bailey J, Cawkwell L, Hills R, Grimstead JW, Jones RE, Britt-Compton B, Fegan C, Baird DM, Pepper C. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 2014, 167(2), 214-223.
  • Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Health Physics 2014, 106(2), 229-246.
  • Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld-Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A, Eckert C. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014, 124(23), 3420-3430.
  • Speedy HE, Di Bernardo MC, Sava GP, Dyer MJS, Holroyd A, Wang YF, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature Genetics 2014, 46(1), 56-60.
  • Migliorini G, Fiege B, Hosking FJ, Ma Y, Kumar R, Sherborne AL, da Silva MI, Vijayakrishnan J, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson P, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Zimmermann M, Bartram CR, Schrappe M, Greaves M, Stanulla M, Hemminki K, Houlston RS. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood 2013, 122(19), 3298-3307.
  • Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JAL, Neben K, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dorner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nature Genetics 2013, 45(10), 1221-1225.
  • Enciso-Mora V, Hosking FJ, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Tomlinson IPM, Allan JM, Taylor M, Greaves M, Houlston RS. Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2012, 26(10), 2212-2215.
  • Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 2012, 119(1), 196-205.
  • Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Neira AG, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nature Genetics 2010, 42(6), 492-494.
  • Allan JM, Sunter NJ, Bailey JR, Pettitt AR, Harris RJ, Pepper C, Fegan C, Hall AG, Deignan L, Bacon CM, Pointon JC, Houlston RS, Broderick P, Mainou-Fowler T, Jackson GH, Summerfield G, Evans PA, Strefford JC, Parker A, Oscier D, Pratt G, Allsup DJ. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia 2010, 24(4), 877-881.
  • Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-Homologous End-Joining Gene Profiling Reveals Distinct Expression Patterns Associated with Lymphoma and Multiple Myeloma. British Journal of Haematology 2010, 149(2), 258-262.
  • Hosking FJ, Leslie S, Dilthey A, Moutsianas L, Wang Y, Dobbins SE, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Taylor M, Greaves M, McVean G, Houlston RS. MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2010, 117(5), 1633-1640.
  • Kane EV, Painter D, Roman E, Allan J, Law G, Lightfoot T. Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. Cancer Epidemiology 2010, 34(2), 136-141.
  • Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Taylor M, Tomlinson IP, Greaves M, Houlston RS. Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. Blood 2010, 115(22), 4472-4477.
  • Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, Smith MT, Allan JM, Taylor GM, United Kingdom Childhood Cancer Study. Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood 2010, 115(19), 3923-3929.
  • Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics 2010, 42(2), 132-136.
  • Pratt G, Fenton JAL, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JAE, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. British Journal of Haematology 2010, 150(3), 371-373.
  • Worrillow L, Roman E, Adamson PJ, Kane E, Allan JM, Lightfoot TJ. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiology 2009, 33(3-4), 257-260.
  • Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nature Genetics 2009, 41(9), 1006-1010.
  • Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J, Tennant TR, Banerjee M, Allan JM, Le Beau MM, Larson RA, Graubert TA, Cox NJ, Onel K. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009, 113(22), 5575-5582.
  • Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MKB, Quirke P, Seymour MT. Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial. Journal of Clinical Oncology 2009, 27(33), 5519-5528.
  • Allan JM. [Meeting Abstract] DNA repair dysfunction and genomic instability in therapy-related malignancy. Mutagenesis 2009, 24(6), 530.
  • Howard R, Gilbert E, Lynch C, Hall P, Storm H, Holowaty E, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa S, Allan JM, Travis L. Risk of Leukemia Among Survivors of Testicular Cancer: A Population-based Study of 42,722 Patients. Annals of Epidemiology 2008, 18(5), 416-421.
  • Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. Journal of Medical Genetics 2008, 45(3), 142-146.
  • Allan JM , Shorto J, Adlard J, Bury J, Coggins R, George R, Katory M, Quirke P, Richman S, Scott D, Scott K, Seymour M, Travis LB, Worrillow LJ, Bishop DT, Cox A. MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. International Journal of Cancer 2008, 123(10), 2456-2459.
  • Ryk C, Routledge MN, Allan JM, Wild CP, Kumar R, Lambert B, Hou S. Influence of DNA repair gene polymorphisms on the initial repair of MMS-induced DNA damage in human lymphocytes as measured by the alkaline comet assay. Environmental and Molecular Mutagenesis 2008, 49(9), 669-675.
  • Scott K, Adamson PJ, Willett EV, Worrillow LJ, Allan JM. Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians. Haematologica 2008, 93(10), 1597-600.
  • Allan JM. Genetic susceptibility to radiogenic cancer in humans. Health Physics 2008, 95(5), 677-686.
  • Di Bernardo M, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman A, Sunter N, Hall AG, Dyer M, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris R, Pettitt A, Hillmen P, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston R. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nature Genetics 2008, 40(10), 1204-1210.
  • Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, Larson RA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008, 112(3), 741-749.
  • Smith AG, Worrillow LJ, Allan JM. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood 2007, 109(3), 1233-1236.
  • Worrillow LJ, Allan JM. Deregulation of homologous recombination DNA repair in alkylating agent-treatedstem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene 2006, 25(12), 1709-1720.
  • Allan JM, Smith AG, Wheatly K, Hills RK, Travis LB, Hill DA, Swirsky DM, Morgan GJ, Wild CP. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004, 104(13), 3872-3877.
  • Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, Holowaty EJ, Kohler BA, Wiklund T, Pukkala E, Roman E, Morgan GJ, Allan JM. An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents. Clinical Cancer Research 2003, 9, 3012-3020.
  • Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roman E, Cartwright RA, Morgan GJ. Polymorphism in glutathione S-transferase PI is associated with susceptibility to chemotherapy-induced leukaemia. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(20), 11592-11597.
  • Allan JM, Hardie LJ, Briggs JA, Davidson LA, Watson JP, Pearson SB, Muers MF, Wild CP. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer. International Journal of Cancer 2001, 91(3), 359-365.

• Book Chapter

  • Travis LB, Bhatia S, Allan JM, Oeffinger KC, Ng A. Second cancers. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Tenth Edition. Wolters Kluwer Health Adis (ESP), 2015.

• Conference Proceedings (inc. Abstracts)

  • Forster V, Nahari M, Martinez-Soria N, Bradburn A, Ptasinska A, Assi S, McNeill H, Bonifer C, Heidenreich O, Allan J. The Leukemia-Associated RUNX1/ETO Oncoprotein Confers a Mutator Phenotype. In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Fondazione Ferrata Storti.
  • Marr H, Gaughan L, Tudhope SJ, Allan JM. Regulation of CD38 in IRF4 in Chronic Lymphocytic Leukaemia. In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Ferrata Storti Foundation.
  • Forster V, Beyerle A, Heidenreich O, Allan J. AML1/ETO Confers a Mutator Phenotype in AML. In: Annual Meeting of the Kind-Philipp Foundation for Leukemia Research. 2012, Wilsede, Germany: Georg Thieme Verlag.
  • Forster VJ, Allan JM, Heidenreich O. The t(8;21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia. In: Blood: American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Forster VJ, Allan JM, Heidenreich O. The t(8,21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Mainou-Fowler T. Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Fowler TM. Mature MicroRNAs Mir 18, 19a, 19b, 17 5p and 92 of the Mir 17 92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology (ASH). 2010, Orlando, Florida, USA: American Society of Hematology.
  • Fordham SE, Matheson EC, Scott K, Irving J, Allan JM. Cellular Response to Cytarabine Is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Fordham SE, Matheson EC, Scott K, Irving J, Allan JM. Cellular Response to Cytarabine is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia. In: Blood: American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. In: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, FL: Blood: American Society of Hematology.
  • Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Onel K, Knight JA, Skol AD, Tennant TR, Banerjee M, Walgren R, Shao J, Allan JM, Le Beau MM, Larson RA, Graubert T, Cox NJ. A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia. In: Blood: 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, California, USA: American Society of Hematology.
  • Allan JM, Sunter N, Hall A, Mainou-Fowler T, Jackson G, Summerfield G, Harris RJ, Pettitt A, Houlston R, Bailey J, Pepper C, Fegan C, Pratt G, Allsup DJ. A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia. In: Blood: 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, California, USA: American Society of Hematology.

• Editorials

  • Fordham SE, Marr H, Allan JM. Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognostication. Leukemia and Lymphoma 2013, 54(3), 447-448.
  • Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Journal of the National Cancer Institute 2012, 104(5), 357-370.
  • Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD. Testicular Cancer Survivorship: Research Strategies and Recommendations. Journal of the National Cancer Institute 2010, 102(15), 1114-1130.

• Letters

  • Forster VJ, Nahari MH, Martinez-Soria N, Bradburn AK, Ptasinska A, Assi SA, Fordham SE, McNeil H, Bonifer C, Heidenreich O, Allan JM. The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype. Leukemia 2016, 30(1), 250-253.
  • Fordham SE, Cole M, Irving JA, Allan JM. Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia. Leukemia 2015, 29(2), 491-494.
  • Sava GP, Speedy HE, Di Bernardo MC, Dyer MJS, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia 2015, 29(3), 748-751.
  • Fordham SE, Matheson EC, Scott K, Irving JAE, Allan JM. DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs. Leukemia 2011, 25(6), 1046-1049.

• Notes

  • Lin W-Y, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann W-K, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Stolzel F, Onel K, Allan JM. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x). Nature Communications 2022, 13(1), 2.
  • Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Gago-Dominguez M, Roobol MJ, Menegaux F, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. Author correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2019, 10(1), 419.
  • Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld-Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A, Eckert C. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430. Blood 2015, 125(5), 890-890.

• Reviews

  • Travis LB, Wahnefried WD, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nature Reviews Clinical Oncology 2013, 10(5), 289-301.
  • Allan JM. The Genetics of Cancer Survivorship. Hematology/Oncology Clinics of North America 2008, 22(2), 257-269.
  • Allan JM, Rabkin CS. Mechanisms of therapy-related carcinogenesis. Pharmacogenomics 2005, 6(6), 615-628.